Viehbacher sets out vision for diversified Sanofi-Aventis
February 11, 2009Sales and Marketing Sanofi
Sanofi-Aventis's new chief executive Chris Viehbacher has presented his vision to renew the company, which will include greater investment in …
Sanofi cleared to buy Zentiva
February 11, 2009Sales and Marketing Sanofi, generics
The European Commission says Sanofi-Aventis can go ahead with its planned acquisition of Czech generics company Zentiva. The Commission had …
Novartis boasts strong sales for 2008
February 11, 2009Sales and Marketing Novartis
Novartis has weathered the financial downturn and delivered a strong performance for 2008. Overall group sales were boosted by 9% …
Health secretary to chair influential pharma group
February 11, 2009Sales and Marketing ABPI, reform
Health Secretary Alan Johnson has been appointed the chair of the Ministerial Industry Strategy Group (MISG) and business secretary Lord …
Industry braced for more mergers
February 11, 2009Sales and Marketing MA, restructure
In retrospect, Pfizer's move to buy another major pharmaceutical company was inevitable. Like its peers, Pfizer has been energetically restructuring …
Pfizer to disclose US clinical trial payments
February 10, 2009Medical Communications ethics
Pfizer has announced plans to disclose payments to healthcare professionals involved in clinical trials. The company will publicly declare all …
Roche hit by strong Swiss franc
February 10, 2009Sales and Marketing Roche
Roche delivered solid performance in 2008, but was unable to shake off the negative effect of a strong Swiss franc. …
Roche bid for Genentech turns ‘hostile’ – but stays friendly
February 10, 2009Sales and Marketing MA, Roche
Roche has launched a renewed bid to buy out Genentech, making a 'hostile' bid for the company by appealing directly …
GSK expands cost cutting drive
February 9, 2009Sales and Marketing GSK, restructure
GlaxoSmithKline has expanded its restructuring plans and will make widespread job cuts in a bid to cut costs throughout its …
India’s Piramal at centre of buy-out speculation
February 9, 2009Sales and Marketing MA, Piramal
Indian pharmaceutical company Piramal has denied that it ready to sell up to one of the global giants of the …
Schering-Plough invests in Scotland drug discovery centre
February 6, 2009Research and Development Merck, Scotland
Schering-Plough is to invest around $30 million in its early drug discovery work in Scotland. The company is investing a …
Job losses mounting at smaller drugmakers
February 5, 2009Sales and Marketing restructure
Another week, and another swathe of job losses across the pharmaceutical sector, with sales and back office staff once again …
What are pharma’s core competencies?
February 5, 2009Research and Development, Sales and Marketing pharma, strategy
Pharma has always been a highly profitable industry, and has historically been among the best performing industrial sectors in terms …
UK pharma to consider ban on doctor gifts
February 5, 2009Medical Communications ABPI, Code of Practice, ethics
All gifts from pharma companies to doctors and to medical students – should be banned, according to a new report …
Mixed reaction for national dementia strategy
February 4, 2009NHS, hc
The government's national dementia strategy, announced this week, has received a mixed reception from patient groups and the media. The …
NICE approves Sutent but rejects rivals
February 4, 2009Sales and Marketing NICE, par
NICE has approved Pfizer's Sutent but rejected three other treatments for kidney cancer. The decision is one of the first …
How ‘in line’ communications won it for Obama
February 3, 2009Medical Communications digi
It is undeniable that we live in an 'online' era: digital media and technology have infiltrated almost every aspect of …
The Brand MOT
February 3, 2009Sales and Marketing branding, marketing
To have a car on the road once it's more than three years old requires an MOT – an annual …
The Pharmafocus Interview: David Gillen
February 3, 2009Research and Development Pfizer, UK, medicines access
David Gillen says he is a born optimist. But Pfizer UK’s medical director says this positive outlook doesn’t blind him …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
